Silver Book Fact

A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s disease and $12,294/QALY for patients with advanced disease.

Hoerger T, Bala M, Rowland C, Greer M, et al. Cost Effectiveness of Pramipexole in Parkinson’s Disease in the U.S. Pharmacoeconomics. 1998; 14(5): 541-57. http://www.ncbi.nlm.nih.gov/pubmed/10344917

Reference

Title
Cost Effectiveness of Pramipexole in Parkinson’s Disease in the U.S.
Publication
Pharmacoeconomics
Publication Date
1998
Authors
Hoerger T, Bala M, Rowland C, Greer M, et al.
Volume & Issue
Volume 14, Issue 5
Pages
541-57
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Medicare Costs, Slowed Progression  
  • One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.  
  • 32 drugs are currently in development for Parkinson’s disease.  
  • A $1 billion-investment in Alzheimer’s research that led to research breakthroughs by 2010 could have a 10-to-1 return by 2015, and a 90-to-1 return by 2050.  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the total costs of care for people with the disease by…